Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | POLD1 | P28340 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327375 | 0.90 | POLB (0.39) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL21506757 | 0.81 | POLB (0.39) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL25141885 | 0.79 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL22778271 | 0.79 | POLB (0.38) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL16627060 | 0.78 | POLB (0.33) | P2RY2P2RY4P2RY14POLBPOLA1 | |
| SCHEMBL24023275 | 0.78 | POLA1 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL271898 | 0.77 | P2RY2 (0.32) | P2RY2P2RY4P2RY6 | |
| SCHEMBL26267548 | 0.76 | FBP1 (0.35) | — | |
| SCHEMBL18462928 | 0.76 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL271833 | 0.76 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | P2RY2 1336/4885P2RY4 1162/4885P2RY14 1834/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | P2RY2 1336/4885P2RY4 1162/4885P2RY14 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.